ESPE Abstracts (2016) 86 P-P1-625

Growth P1

2nd Year Pharmacokinetic and Pharmacodynamic Modeling of Long-Acting Human Growth Hormone (MOD 4023) in Growth Hormone Deficient Children

Dennis M. Fishera, Michal Jaron Mendelsonb, Shelly Vanderb, Ronit Korenb & Gili Hartb


aP Less Than, San Francisco, USA; bOPKO Biologics, Nes Ziona, Israel

Background: OPKO Biologics is developing MOD-4023, a long-acting growth hormone (GH), intended for weekly dosing for the treatment of idiopathic GH deficiency in children. At ESPE2015, we presented pharmacokinetic (PK) and pharmacodynamic (PD, based on IGF-1) models for weekly MOD-4023 administration in children aged 3–11 years. Those models were based on data collected during the ‘PKPD period’ (the second steady state dose of MOD-4023) and monthly values during the remainder of the first year of treatment. We now extend those analyses to data collected during the second year of treatment.

Objective and hypotheses: To evaluate whether the PK and PD models developed from data during the first year of treatment with MOD-4023 apply to data during the second year of open-label treatment.

Methods: After one year of treatment, children treated with weekly MOD-4023 continued on the same dose of MOD-4023 (0.25, 0.48, or 0.66 mg/kg); children treated with daily Genotropin were reassigned to one of the three weekly MOD-4023 dose levels. Blood was sampled monthly at ~4 days post-dose to determine concentrations of MOD-4023 and IGF-1. A dataset was assembled that included values through 2 years of treatment. MOD-4023 concentrations were fit to a 2-compartment linear compartmental model. IGF-1 data were fit to an indirect PD model in which MOD-4023 increases input of IGF-1 to plasma, from which there is first-order elimination. We evaluated whether data from the second year was predicted by data from the first year.

Results: Analyses are not yet complete.

Conclusion: Clinical data indicate that efficacy of MOD-4023, particularly at the higher dose levels, is preserved through it least 2 years of treatment. The current analysis will evaluate whether PK and PD characteristics predicted from the first year of treatment are preserved during the second year.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.